Different forms of prefrontal transcranial stimulation and brain-derived neurotrophic factor in prediction of antidepressant efficacy of brain stimulation

Different forms of prefrontal transcranial stimulation and brain-derived neurotrophic factor in prediction of antidepressant efficacy of brain stimulation - Brain-derived neurotrophic factor and the antidepressant efficacy of prefrontal transcranial stimulation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033334

Enrollment

120

Registered

2018-07-09

Start date

2018-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A treatment option for Medication-resistant depression

Interventions

Left DLPFC intermittent TBS group (1 session/day, 5 days/week,4weeks)

80% active motor threshold, 1800 pulses once Left DLPFC 10Hz rTMS group (1 session/day, 5 days/week,4weeks)

100% motor threshold,1600 pulses once Sham group(1 session/day, 5 days/week,4weeks) randomly divided to half with TBS and half with rTMS parameters using a sham coil.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult patients with the relapse of major depressive episode

Exclusion criteria

Exclusion criteria: Patients with schizophrenia, organic mental disorder, and major physical illness; with brain implants or cardiac pacemakers; pregnancy; or who having strong suicidal risk; contraindication for MRI evaluation.

Design outcomes

Primary

Measure	Time frame
the interaction between the efficacy of brain stimulation and BDNF genotype.	—

Secondary

Measure	Time frame
the changing of HDRS-17 and response rate (week-4 vs. baseline) after treating by 4-week prefrontal brain stimulation;Response rate; Computerized rACC-engaging cognitive task(RECT)and EEG; Maudsley Staging method for refractoriness;the changing of HDRS-17 and response rate of the 12-week follow-up after the treatment (week-16 vs. baseline) after treating by 4-week brain stimulation; Young mania Rating scale; Clinical Global Index; Depression and somatic symptoms; Life stress scale; functional changing of PET/MRI after prefrontal transcranial stimulation; the comparison between 5 cm rule and neuro-navigation for localization.	—

Measure

Time frame

the changing of HDRS-17 and response rate (week-4 vs. baseline) after treating by 4-week prefrontal brain stimulation;Response rate; Computerized rACC-engaging cognitive task(RECT)and EEG; Maudsley Staging method for refractoriness;the changing of HDRS-17 and response rate of the 12-week follow-up after the treatment (week-16 vs. baseline) after treating by 4-week brain stimulation; Young mania Rating scale; Clinical Global Index; Depression and somatic symptoms; Life stress scale; functional changing of PET/MRI after prefrontal transcranial stimulation; the comparison between 5 cm rule and neuro-navigation for localization.

—

Countries

Asia(except Japan)

Contacts

Public ContactCheng-Ta Li

Taipei Veterans General Hospital, Taiwan Taipei Veterans General Hospital, Taiwan

on5083@msn.com+88628757027

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026